Breaking Finance News

BioSpecifics Technologies (NDAQ:BSTC) target price lowered to $65.00, issued a report today by H.C. Wainwright

Just yesterday BioSpecifics Technologies (NDAQ:BSTC) traded 0.50% higher at $43.99. BioSpecifics Technologies’s 50-day moving average is $49.89 and its 200-day moving average is $52.12. The last closing price is down -6.96% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.02% over the same time period. 12,405 shares of BSTC traded hands, down from an average trading volume of 27,000

BioSpecifics Technologies (NDAQ:BSTC) had its target price lowered to $65.00 by H.C. Wainwright in a report released 11/13/2017. The new target price indicates a possible upside of 0.48% based on the company's previous closing price.

Recent Performance Chart

BioSpecifics Technologies (NDAQ:BSTC)

BioSpecifics Technologies has 52 week low of $35.79 and a 52 week high of $58.79 with a PE ratio of 29.75 and has a market capitalization of $0.

In addition to H.C. Wainwright reporting its target price, a total of 1 broker has issued a report on the stock. The consensus target price is $76.00 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About BioSpecifics Technologies (NDAQ:BSTC)

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren's contracture and Peyronie's disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *